Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MSI Methylation Sciences Inc.

methylationsciences.com

Latest From CircuLite Inc.

Heart Failure: Next-Gen VADs Fuel Optimism Amid Challenges

Although near-term challenges have slowed growth in the market for left ventricular assist devices (LVADs), companies are developing new, less invasive VADs with improved pump designs to further improve patient outcomes and allow for a wider application of the therapy in treating heart failure. These next-generation VADs are fueling long-term optimism in the market for mechanical circulatory support, which remains one of the more attractive opportunities in the cardiovascular space.

Medical Device Europe

Forbion’s New Fund

Dutch venture capital firm, Forbion Capital Partners, has launched a new €92 milion ($116 million) life science fund to invest in 12 to 15 new companies. This is first close for the new fund called Forbion Capital Fund III, en route to a target of €150 to €200 million.

Medical Device

European Markets Show Pockets Of Strong Growth For Cardiovascular Devices

The big five European Union markets – Germany, France, the UK, Spain, and Italy – are expected to see strong growth in some of the more common cardiovascular device implant procedures over the next four years, with ventricular assist device (VAD) implantations topping the list. All five major EU markets are forecast to experience healthy mid-teen compound annual growth rates in VAD implantation volume, according to recently published European procedure volume reports from Medtech Insight.

Medical Device

Deals In Depth: December 2013

Following the loss of patent protection on its antidepressant Lexapro in 2012, Forest added a new drug to its neurology portfolio, licensing US rights to Merck’s antipsychotic Saphris for $240 million; AstraZeneca took full control of BMS’s global diabetes business, paying $2.9 billion up front. Financing in December lagged behind the previous month’s figures in both biopharma and device.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Nutraceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • MSI Methylation Sciences Inc.
  • Senior Management
  • David MacDonald, PhD, CTO
    Nancy Harrison, Pres.
    Steven Targum, MD, CMO
  • Contact Info
  • MSI Methylation Sciences Inc.
    Phone: (604) 435-5155
    108-4475 Wayburne Dr.
    Burnaby, V5G 4X4
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register